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Copyright © 2015 Håkon Reikvam et al.This is an open access article distributed under theCreative CommonsAttribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Allogeneic stem cell transplantation is commonly used in the treatment of younger patients with severe hematological diseases,
and endothelial cells seem to be important for the development of several posttransplant complications. Capillary leak syndrome
is a common early posttransplant complication where endothelial cell dysfunction probably contributes to the pathogenesis. In
the present study we investigated whether the pretreatment serum metabolic profile reflects a risk of posttransplant capillary leak
syndrome. We investigated the pretransplant serum levels of 766 metabolites for 80 consecutive allotransplant recipients. Patients
with later capillary leak syndrome showed increased pretherapy levels of metabolites associated with endothelial dysfunction
(homocitrulline, adenosine) altered renal regulation of fluid and/or electrolyte balance (betaine,methoxytyramine, and taurine) and
altered vascular function (cytidine, adenosine, and methoxytyramine). Additional bioinformatical analyses showed that capillary
leak syndrome was also associated with altered purine/pyrimidine metabolism (i.e., metabolites involved in vascular regulation
and endothelial functions), aminoglycosylation (possibly important for endothelial cell functions), and eicosanoid metabolism
(also involved in vascular regulation). Our observations are consistent with the hypothesis that the pretransplant metabolic status
can be a marker for posttransplant abnormal fluid and/or electrolyte balance.
1. Introduction
Allogeneic hematopoietic stem cell transplantation (allo-
SCT) is used in the treatment of severe hematological dis-
eases, especially high-risk malignancies [1, 2]. The treatment
is associated with a relatively high risk of transplant-related
morbidity and mortality due to severe posttransplant com-
plications. Endothelial cells seem to be involved in the patho-
genesis of several of these complications, that is, venooc-
clusive disease, acute graft versus host disease (GVHD),
capillary leak syndrome, and microangiopathic hemolysis
[3–5]. Furthermore, several studies have demonstrated that
pretransplant clinical factors are important for the risk of
posttransplant complications; this is true both for organ
toxicity and immune-mediated complications and these fac-
tors include both disease stage and previous treatment, type
of conditioning therapy, and comorbidity (i.e., additional
complicating diseases) [6, 7]. Recent studies suggest that even
preconditioning factors are important at least for the devel-
opment of immune-mediated posttransplant complications
[8, 9].
The hypothesis that endothelial cells are involved in
the development of posttransplant complications is largely
based on the observations of altered levels of endothelial
markers either prior to [9], or during the development of
the complications [3–5, 10–13]. The molecular mechanisms
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Table 1: Patients with and without capillary leak syndrome: a comparison of clinical characteristics.
Weight increase
All patients <5 kg (𝑛 = 39) ≥5 kg (𝑛 = 41) 𝑝 value
Demographic data
Age (years) 44 (15–69) 42 (15–69) 51 (20–67) 0.1066
Gender (female/male) 29/51 13/26 16/25 0.5966
Weight (kg) 71.4 (41.5–110) 73 (41.5–110) 70 (46.5–133) 0.7031
Height (cm) 176 (149–197) 179 (149–193) 174 (158–197) 0.4102
BMI (kg/m2) 23.2 (16.6–39.7) 23.5 (16.6–36.5) 23.1 (17.9–39.7) 0.2852
Diagnosis
AML 35 19 16
MDS 15 5 10
ALL 18 11 7
CML 4 1 3
CMML 2 0 2
CLL 1 1 0
PMF 2 1 1
AA 3 0 3
Body weight
Weight increase (kg) 5.0 (0–16.1) 3.2 (0–4.8) 7.0 (5.0–16.1) <0.0001
Day of maximal weight 6 (−8–44) −1 (−8–13) 9 (−5–44) 0.0011
Acute GVHD (yes/no) 42/28 24/12 18/16 0.2414
Reconstitution
Neutrophil (day post-SCT) 15 (6–52) 15 (6–29) 16 (11–52) 0.2848
Platelets (day post-SCT) 15 (9–33) 14 (9–29) 16 (9–33) 0.2076
Baseline pretransplant status
Leukocytes (×109/L) 3.9 (0.5–44.3) 3.5 (0.7–11.8) 4.8 (0.5–44.3) 0.1972
Hb (g/dL) 10.5 (7.8–14.1) 10.6 (7.8–14.0) 10.4 (7.9–14.1) 0.4440
Platelets (×109/L) 143 (10–721) 205 (10–721) 119 (10–554) 0.0147
CRP (mg/L) 5 (1–120) 5 (1–64) 6 (1–120) 0.1660
LDH (IU/dL) 185 (92–1665) 190 (129–489) 174 (92–1665) 0.1780
Unless otherwise stated values are given as median (variation range). Height and weight were registered at the start of conditioning therapy. For statistical
analysis the Mann-Whitney test was used to compare continues variables and the Chi-square test for categorical variables.
AA, aplastic anemia; ALL; acute lymphoblastic leukemia; AML, acute myelogenous leukemia; BMI, body mass index; MDS, myelodysplastic syndrome; CLL,
chronic lymphocytic leukemia; CML, chronicmyelogenous leukemia; CMML, chronicmyelomonocytic leukemia; CRP, C-reactive protein; GVHD, graft versus
host disease; Hb, hemoglobin; LDH, lactate dehydrogenase; PMF, primary myelofibrosis; WBC, white blood cell count.
causing altered endothelial cell functions in allotransplant
recipients are largely unknown. However, metabolic factors
may be important for regulation of endothelial cell functions
or the fluid/electrolyte balance, and we therefore investigated
whether the preconditioning/pretransplant metabolic serum
profile showed any associations with the later development
of capillary leak syndrome. This is a relatively frequent
posttransplant complication where endothelial, vascular, or
renal dysfunctions are likely to contribute.
2. Material and Methods
2.1. Patients. The study was approved by the local Ethics
Committee (Regional Ethics Committee III, University of
Bergen, Norway) and samples were collected after written
informed consent. The study included 80 consecutively allo-
transplanted adult patients (51 men and 29 women; median
age 44 years with range 16–69 years) from a defined geo-
graphic area (Norwegian Health Regions III, IV, and V) and
transplanted with a family donor. The decision to perform
an allotransplantation was taken by the Norwegian Advisory
Board for Stem Cell Transplantation and based on national
guidelines. Thus, our study is population-based and includes
an unselected and consecutive group of well-characterized
patients.
All samples were collected before start of conditioning
therapy (median 19 days before). The clinical characteristics
of the patient are given in Table 1. Most patients received
GVHD prophylaxis with cyclosporine A and methotrexate,
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and only two patients received cyclosporine A alone. Patients
were transplanted with granulocyte colony-stimulating fac-
tor (G-CSF) mobilized peripheral blood stem cells derived
from HLA-matched family donors (aplastic anemia patients
received bone marrow grafts). Neutrophil reconstitution was
defined as three consecutive days with neutrophil counts of at
least 0.2 × 109/L and platelet reconstitution as stable platelet
counts exceeding 20 × 109/L for at least 3 consecutive days.
All patients were carefully examined for and classified with
regard to comorbidity according to Sorror [7]; none of the
patients had liver or renal disease and the overall comorbidity
score was low (1 or 0). Sinusoidal obstruction syndrome was
not diagnosed in any patient.
2.2. Diagnosis of Capillary Leak Syndrome. Capillary leak
syndrome was defined as at least 10% weight gain during
24 hours despite diuretic therapy. The patients’ weight was
registered twice daily, and according to the department’s
guidelines patients then received 20–40mg of furosemide
if the weight gain exceeded 2.0 kg compared with the body
weight registered immediately before start of the condition-
ing therapy. A clinical evaluation was in addition done twice
daily by one of the physicians from the allotransplantation
team, and it was then decided whether additional diuretic
treatment should be administered. The intravenous fluid
administration during conditioning therapy and following
stem cell transplantation was administered to maintain a
relatively high diuresis (i.e., the amount of intravenous fluid
administration was decided based on a volume parameter
independent of the patients’ body weight), and for this reason
we used a definition of capillary leak syndrome based on the
absolute and not the relative weight increase.
2.3. Preparation of Serum Samples. All venous blood samples
were collected into sterile plastic tubes (BD Vacutainer SST
Serum Separation Tubes, Becton-Dickenson; Franklin Lakes,
NJ, USA) and allowed to coagulate for 120 minutes at
room temperature (18∘C) before centrifugation (300 g for 10
minutes) and serum collection. All sampleswere immediately
frozen at −70∘C until being analyzed.
2.4. Analysis of Metabolite Serum Levels. Metabolomic pro-
filing analysis of all samples was carried out in collaboration
with Metabolon [14]. Each sample was accessioned into the
Metabolon LIMS system and was assigned by the LIMS
a unique identifier used to track all sample handling and
results.The samples (and all derived aliquots) were tracked by
the LIMS system. Sampleswere prepared using the automated
MicroLab STAR system (Hamilton Company, Bonaduz,
Switzerland). A recovery standard was added prior to the first
step in the extraction process for quality control purposes.
To remove protein, to dissociate small molecules bound
to protein or trapped in the precipitated protein matrix,
and to recover chemically diverse metabolites, proteins were
precipitated with methanol under vigorous shaking for 2
minutes followed by centrifugation.The resulting extract was
divided into four fractions: one for analysis by UPLC-MS/MS
with positive ion mode electrospray ionization, one for anal-
ysis by UPLC-MS/MS with negative ion mode electrospray
ionization, one for analysis by GC-MS, and one sample that
was reserved for backup. Samples were placed briefly on a
Zymark TurboVap (KcKinley Scientific, Sparta, NJ, USA) to
remove the organic solvent. For LC, the samples were stored
overnight under nitrogen before preparation for analysis. For
GC, each sample was dried under vacuum overnight before
preparation for analysis. A total of 766 metabolites were
analyzed in all samples. These metabolites could be divided
into the eight main categories (corresponding number of
metabolites): amino acids (156), peptides (92), carbohydrates
(24), energy metabolism (9), lipids (298), nucleotides (36),
cofactors/vitamins (27), and xenobiotics (124).
2.5. Analysis of Serum Cytokine Levels. Cytokine levels were
determined by Luminex analyses (R&D Systems; Abingdon,
UK) and included the following: (i) the immunomodulatory
Interferon-𝛾 (IFN-𝛾), CD40 ligand (CD40L), and tumor
necrosis factor-𝛼 (TNF-𝛼); (ii) the interleukins IL-1𝛼, IL1-
𝛽, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-8/CXCL8, IL-10, IL-12,
IL-13, and IL-17; (iii) the chemokines CCL3, CCL4, CCL5,
CCL11, CXCL5, CXCL10, and CXCL11; and (iv) the growth
factors basic fibroblast growth factor (bFGF), granulocyte
macrophage colony-stimulating factor (GM-SCF), G-SCF,
vascular endothelial growth factor (VEGF), thrombopoietin
(Tpo), epithelial growth factor (EGF), hepatocyte growth
factor (HGF), and Leptin. All analyses were performed in
duplicates strictly according to the manufacturer’s instruc-
tions.
2.6. Bioinformatical and Statistical Analyses. Bioinformatical
analyses were performed using the J-Express (MolMine AS,
Bergen, Norway) [15]. For hierarchical clustering all values
were median variance standardized and log(2) transformed.
The complete linkage was used as linkage method, and for
distancemeasure the Euclidean correlationwas used. Statisti-
cal analyses were performed using the Statistical Package for
the Social Sciences (SPSS) version 15.0 (SPSS Inc., Chicago,
IL, USA). The Chi-Square test was used to compare different
groups. Unless otherwise stated p values< 0.05 were regarded
as statistically significant.
3. Results and Discussion
3.1. Capillary Leak Syndrome Is a Frequent Complication
after Allogeneic Stem Cell Transplantation. Capillary leak
syndrome characterized by a weight increase ≥ 5 kg/24 hours
was diagnosed in 41 patients; patients with and without the
syndrome did not differ with regard to age, gender, bodymass
index, later acute GVHD, or hematological reconstitution
(Table 1). They did not differ with regard to pretransplant
hemoglobin level, peripheral blood white blood cell counts,
serum CRP, or serum LDH levels either. However, patients
with later capillary leak syndrome showed lower peripheral
blood platelet counts (see Table 1). According to the defini-
tion patients with capillary leak syndrome showed a larger
























































Figure 1: Random forest analysis of pretransplant metabolite levels: identification of metabolites showing altered serum levels in patient with
capillary leak syndrome. Random forest analysis could distinguish between the metabolic signatures of patients with and without capillary
leak syndrome with a predictive accuracy of 62%, suggesting that these metabolites are candidate biomarkers for increased risk of capillary
leak syndrome. The figure presents the top 30 metabolites based on their importance to separate the two patient groups. The different colors
reflect the metabolite classification as indicated at the bottom of the figure.
maximal weight increase occurred later than for the other
patients (median 1 day before transplant versus 9 days after
transplant).
3.2. Patients with Posttransplant Capillary Leak Syndrome
Show Increased Pretransplant Levels of Several Metabolites
Known to Regulate Endothelial Function, Renal Function,
or Vascular Permeability. We performed a random forest
analysis (i.e., a supervised classification statistical analysis)
to identify metabolites that are candidate biomarkers for
predicting risk of capillary leak syndrome. We could then
identify metabolic biomarkers that distinguished between
patients with and without capillary leak syndrome with a
predictive accuracy of 62% (Figure 1). This number is greater
than the random chance alone (∼50%), suggesting that the
identified metabolites are candidate biomarkers for predict-
ing risk of capillary leak syndrome. The figure shows the
top 30 metabolites ranked according to their importance for
separation of the two groups. A majority of these metabolites
(12 of all the 30, 6 of the 7 highest ranked) are involved in
amino acid metabolism.
The biological characteristics of the 7 metabolites show-
ing strongest association with development of capillary leak
syndrome (Figure 1) are summarized in Table 2 [16–32].
Firstly, homocitrulline and ornithine are linked together in
the urea cycle [16], but homocitrulline is also a product
derived from carbamylation, that is, a nonenzymatic post-
translational protein modification with binding of isocyanic
acid to amino groups. Serum homocitrulline levels may
therefore reflect the overall carbamylation activity including
carbamylation of tissue proteins [17]. Both the serum levels
and protein carbamylation seem to be important in vascular
biology [17] and have been associated with risk of cardiovas-
cular death [18] as well as increased mortality in renal failure
[19] and endothelial dysfunction through carbamylation of
low density lipoprotein [20]. Secondly, methoxytyramine
is the O-methylated metabolite of dopamine [23] and is
therefore used as a marker for dopamine-producing tumors
[24], but dopamine is also involved in the renal regulation of
body fluid and electrolyte balance [25, 26] and regulation of
vascular permeability [27]. Betaine also seems to have a role
in vascular biology/fluid balance and adaptation to hyper-
tonic stress [22]. Thirdly, 1-methylhistidine is derived from
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Table 2: The biological functions of the seven metabolites showing the largest difference when comparing pretransplant serum levels for
patients with and without posttransplant capillary leak syndrome (random forest analysis, see Figure 1): a summary of known effects on
endothelial cells, renal function, and vascular permeability.
Metabolite
(main class) Biological functions relevant for fluid and electrolyte balance
Homocitrulline
(amino acid)
Homocitrulline and ornithine are linked together in the urea cycle, and genetic defects in ornithine transport
into mitochondria cause increased systemic homocitrulline levels [16]. Homocitrulline is also a product
derived from carbamylation, a nonenzymatic posttranslational protein modification with binding of
isocyanic acid to 𝜀-amino groups of lysine, and serum/plasma homocitrulline levels may reflect the overall
carbamylation process including carbamylation of tissue proteins [17]. Serum homocitrulline levels and
carbamylation seem important for vascular biology, and high plasma citrulline is associated with severe
coronary artery disease [17], risk of cardiovascular death [18], and increased mortality in renal failure [19]. It
is not known whether homocitrulline/carbamylation is important for regulation of vascular permeability or
regulation of paracellular or transendothelial transport, but carbamylation of low density lipoprotein induces
endothelial cell dysfunction [20].
1-Methylhistidine
(amino acid)
Anserine (beta-alanyl-1-methyl-L-histidine) is present in many kinds of vertebrate muscles but not in human
muscles; 1-methylhistidine is derived from metabolism of anserine and may thus reflect the nutritional status
of the patients [21].
Betaine
(amino acid)
Betaine is found in many foods including spinach and wheat, and it accumulates in renal medullary cells
during adaptation to hypertonic stress [22]. The primary role of betaine in the kidney seems to be
osmoprotection; intracellular accumulation is then mediated by the betaine/GABA transporter. Thus, betaine
seems to be involved in renal regulation of fluid balance.
Methoxytyramine
(amino acid)
This is the O-methylated metabolite of dopamine [23] and recent studies suggest that it can be used as a
marker for dopamine-producing tumors [24]. Dopamine is involved in renal regulation of body fluid and
electrolyte balance; these effects are mediated through binding to specific dopamine receptors that regulate
the function of Na+/K+-ATPase [25]. Animal studies suggest that altered dopamine-induced signaling is
important for fluid retention in nephrotic syndrome [26]. Thus, the increased methoxytyramine levels may
reflect altered dopamine metabolism that contributes to fluid retention through a renal mechanism.




Methionine can be oxidized to methionine sulfone during food processing; this metabolite seems to reduce
the effectiveness of gut proteases to digest dietary proteins and its plasma/serum levels may reflect the
nutritional status [28, 29].
Caffeine
(xenobiotics)
Serum caffeine levels are not only determined by the intake but are rather determined by several additional




This is a nonprotein amino acid found in various plants [32]; its level may thus be related to the nutritional
status.
metabolism of anserine and possibly reflects the nutritional
status [21]; the same may be true for methionine sulfone
[28, 29] and N𝛿-acetylornithine [32]. Finally, serum caffeine
levels are not only determined by oral intake but also by
several other factors including physical activity, the fat mass,
and carbohydrate intake (i.e., nutritional status) [30, 31]. To
conclude, several metabolites showing strong associations
with fluid retention may influence endothelial cell function,
modulate renal regulation of fluid/electrolyte homeostasis, or
reflect the nutritional balance.
3.3. The Pretransplant Metabolite Profile Can Be Used to
Distinguish between Patients with and without Posttransplant
Capillary Leak Syndrome. We performed an unsupervised
hierarchical clustering analysis (Figure 2) based on the 15
highest ranked metabolites from the random forest analysis
(Figure 1).Theuppermain cluster includedmost of the amino
acid metabolites whereas the lower included caffeine, cyclo
(leu-pro), 3-methyl catechol sulfate, and o-cresol sulfate.
The patients formed two main clusters with 40 patients each.
The left cluster included relatively few patients with capillary
leak syndrome (14 out of 40 patients) and the right cluster
included a majority of patients with capillary leak syndrome
(27 out of 40 patients); this difference in frequency of patients
with capillary leak syndrome reached statistical significance
(Chi-square test, p = 0.0036).
3.4. Patients with Capillary Leak Syndrome Show Altered
Pyrimidine and Purine Metabolism: Possible Effects on
Endothelial Cells and Vascular Smooth Muscle Cells. We did
a pathway enrichment analysis to compare patients with
and without capillary leak syndrome. Several metabolic
subclasses/subpathways were enriched among capillary leak
patients; the pathways showing an enrichment value >5
(p < 0.01) are presented in Figure 3 and an overview of
their significantly altered metabolites is presented in Table 3
[33–42]. A hierarchical clustering analysis based on all the
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Figure 2:Themetabolic profile can be used to distinguish patient with and without capillary leak syndrome.We performed an unsupervised
hierarchical clustering analysis (Euclidean distance measure with complete linkage) based on the 15 highest ranked metabolites from the
random forest analysis (Figure 1). The figure demonstrates the heat map with corresponding denograms. The patient classification is shown
at the top; those patients with capillary leak syndrome and weight increase ≥5 kg are marked with red and the others are marked with green.
The left main cluster included a majority of patients without capillary leak syndrome (14 out of 40 patients) whereas a majority of the patients
in the right main cluster developed the syndrome (27 out of 40 patients; Chi-square test, p = 0.0036).
Methionine, cysteine, SAM, and taurine metabolism
Purine metabolism, adenine containing
Urea cycle; arginine and proline metabolism
Eicosanoid
Purine metabolism, guanine containing
0 5 10 15 20 25 30
Aminosugar metabolism
Pyrimidine metabolism, cytidine containing
Figure 3: Pathway enrichment analysis of metabolic profiles associated with capillary leak syndrome. The pathway enrichment analysis
was used to identify metabolites/pathways that were altered in pretransplant samples derived from patients with capillary leak syndrome
(i.e., weight increase >5 kg) compared to patients with lower weight increase (i.e., <5 kg). A pathway enrichment value >1 indicates that the
pathway was increased in patients with an acute phase reaction.The top rankedmetabolic pathways (p < 0.01, enrichment value >5) identified
by this comparison are given in the figure.
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Table 3: The table shows the following: (I) the main metabolic classification (referred to as Super Pathway in the Supplementary Table
in Supplementary Material available online at http://dx.doi.org/10.1155/2015/943430) together with the number of significantly altered
metabolites belonging to this class relative to the total number of examined metabolites from this class; (II) the subclass(es) (subpathway,
see also Figure 3) within the corresponding main class showing an enrichment value >5 followed by the number of significantly altered single
metabolites relative to the total number of investigated metabolites for this subclass; and (III) the single metabolites showing significant
differences, whether they were increased (↑) or decreased (↓) for patients with capillary leak syndrome, and a brief summary of known and
relevant functional effects on endothelial cells, renal function, or vascular biology.Themain class/subclasses are ranked according to the score
presented in Figure 3 (value given in parenthesis after the subclass identification). The nucleotide main class (super pathway) included three
different subclasses/subpathways that showed an enrichment value >5; 6 of the 36 metabolites in the nucleotide class differed significantly
between the two patient subsets (2 in each subclass, indicated as 6/36). The corresponding numbers for the Main Class Amino acids were











Animal models suggest that cytidine can function as a cardiovascular
regulator through binding to adenosine A1 and A2 receptor [33].
Carbohydrate 2/24 Aminosugarmetabolism 2/3 (17.02)
↑glucuronate
Glucuronate is important for the synthesis of several glycoproteins (see
Table 4).
↑erythronate
Erythronic acid is important in mitochondrial metabolism, and it is






There is a metabolic interaction between adenosine and guanosine
metabolism; extracellular ADT and ATP are known angioregulatory
mediators [35].
Lipid 1/303 Eicosanoid 1/6 (8.51)
↑Thromboxane B2
Thromboxane B2 is the main degradation product of Thromboxane A2 [36]
that can be released by endothelial cells and bind to specific receptors
expressed both by endothelium and smooth muscle vascular cells [36–38].







Both metabolites are important for the urea cycle; ornithine enters
mitochondria and reacts with carbamoyl phosphate to form citrulline that






Adenosine is a well-characterized cardiovascular regulator and binds to







↑N-acetylmethionine; ↑N-formylmethionine; ↑Methionine sulfone
N-acetylmethionine can be formed by normal cells from methionine, but it
is also a bioavailable form of methionine in humans [41]. Methionine
sulfone may reflect the nutritional status.
↓hypotaurine; ↓taurine
As reviewed recently taurine is a 𝛽-amino acid that is not incorporated into
proteins and can serve as an intracellular osmolyte [42]. It is one of the
major osmolytes (together with betaine) in the renal medulla. A renal
adaptive response to dietary intake seems to conserve the total taurine
body pool through the balance between reabsorption and excretion.
Taurine seems to be a regulator of renal blood flow and influences the flow
within all types of vessels, and it also seems to stabilize the endothelium.
pathways (Figure 3) could not distinguish between patients
with and without capillary leak syndrome (data not shown).
The term “Pyrimidine metabolism, cytidine containing”
(enrichment value 25.53) got the highest score in this analysis
and “Purine metabolism guanine containing” got the second
highest (17.02). Purinergic signaling is important for regu-
lation of vascular tone and there is a metabolic interaction
between guanine and adenine; ATP then seems to have a dual
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Claudin-1, -2, and -4
Two in silico studies suggest that claudins can be glycosylated, and there seems to
be a functional interplay between glycosylation and phosphorylation. For claudin-1
it has been suggested that alternate phosphorylation/glycosylation on Ser192,




An in silico study suggests that human occludin can be O-𝛽-glycosylated, and for
Ser408 and Ser490 there may be a functional interplay between phosphorylation




Connexins show posttranscriptional modulations through glycosylation but also
through phosphorylation, proteolysis, acetylation, nitrosylation, ubiquitination,
lipidation, hydroxylation, methylation, and deamidation.
[52]
Connexin 43
Connexin 43 is expressed by endothelium and is involved in regulation of
permeability. Glycosylation of connexin 43 is important for the regulation of their





Modification of N-linked glycanes can affect their adhesive functions;





CD147 is an interaction partner of Caveolin-1; a significant biochemical property of
CD147 is its high level of glycosylation. Glycosylation is important for its biological
functions and glycosyltransferases involved in the biosynthesis of CD147
N-glycanes. Glycosylated extracellular matrix metalloproteinase inducer specifically
associates with caveolin-1.
[58–60]
function as it can be released as a neurotransmitter to cause
vasoconstriction or be released by endothelial cells as a stress
response leading to vasodilation [35].
Nucleotides bind to several P2X and P2Y receptors that









that bind ATP, ADP, UDP, and UTP) and
vascular smooth muscle cells [35]. Endothelial cells are
thus important for the vascular purine effects because they
express these receptors and thereby are targets for nucleotides
released frommyocytes and blood cells but also because they
are a source of purines and contribute to purine metabolism
through expression of cell surface ectonucleotidases that
regulate local nucleotide levels [35]. The dominant receptors
on endothelial cells are A








3.5. Capillary Leak Syndrome Is Associated with Altered
Pretransplant Aminoglycosylation: Relevance for Vascular Gly-
cocalyx, Glycosylation of Endothelial Surface Molecules, and
Vascular Permeability. The endothelial cell barrier is reg-
ulated by cell-cell and cell-extracellular matrix adhesion.
The glycocalyx is an extracellular covering on the luminal
side of the endothelium, and it is an important regulator
of endothelial permeability together with the transcellular
and paracellular pathways described below [44]. This surface
layer consists of proteoglycans, glycosaminoglycans, and
adsorbed plasma proteins; its thickness as well as its negative
charging varies between vascular beds/tissues [44]. This bar-
rier functions as a sieve allowing transendothelial transport
of molecules but inhibiting cellular extravasation. Several
experimental studies suggest that the degree of glycosylation
of the surface layer molecules is an important regulator
of vessel permeability; and the permeability can be altered
through hydrolysis of sialic acid moieties, neuraminidase
treatment, and degradation of heparan sulphate [44].
Endothelial cells express several adhesion molecules that
are important for leukocyte trafficking and these molecules
can beN-glycosylated; this is true for ICAM-1, P-selectin, and
E-selectin [45]. The carbohydrate profile of the endothelial
surface differs between vascular beds and glycosylation is
a dynamic process that is further modified during inflam-
mation. Thus, glycosylation is an important regulator of
vessel/endothelial permeability both through modulation of
the surface glycocalyx and the luminal endothelial cell surface
molecules.
Themechanisms for regulation of endothelial permeabil-
ity were reviewed recently [46]. The endothelial permeability
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for molecules from 0.1 nm (sodium ions) up to 3.6 nm
shows an inverse correlation withmolecular size, whereas the
permeability seems independent of the molecular diameter
for larger molecules [44, 47]. These differences correspond
to two different transport mechanisms. The transport of the
largermolecules (e.g., immunoglobulin IgG, albumin) occurs
through a transcellular mechanism referred to as transcytosis
or vesicular transport, whereas the smaller molecules (i.e.,
water and ions) can pass through interendothelial junctions
in a paracellular pathway [46]. The regulation of both these
pathways is important to maintain the endothelial barrier.
The paracellular pathway is regulated by several junctional
proteins: (i) tight junctions are formed by occludins, claudins,
and junctional adhesion molecules (JAM) and especially
JAM-B is detected in endothelial cells; (ii) GAP junctions
are formed by connexins; and (iii) adherent junctions rep-
resent homotypic adhesion between cells and are formed
by vascular endothelial (VE) cadherins. Tight junctions and
adherent junction are linked to the intracellular cytoskeleton,
whereas the GAP junctions represent channels between cells
that allow molecular exchange of signaling molecules and
ions. As can be seen from Table 4 the function of several
molecules involved in the formation of all these permeability-
regulating structures can be modulated by glycosylation
[48–60].
3.6. Increased Pretransplant Thromboxane B2: Is Altered
Eicosanoid Metabolism Important in the Development of
Capillary Leak Syndrome? Thromboxane B
2
was the only
mediator in this class that was significantly altered (Table 3).
This mediator is the main degradation product of Throm-
boxane A
2
[36] that can be released by endothelial cells
and bind to specific receptors expressed both by endothe-
lium and vascular smooth muscle cells [36–38]. This recep-
tor ligation/activation usually promotes vasoconstriction
[36].
3.7. Pretransplant Cytokine Profiles Reveal Patients with
Increased Risk for Capillary Leak Syndrome. Serum cytokine
profiles were available for the first 56 out of our 80 patients.
We first compared the serum levels of each cytokine for
patients with and without capillary leak syndrome. CD40L
was then the onlymediator that differed significantly between
the two groups (p = 0.0061, Mann-Whitney𝑈 test), and these
levels were lower in patients with capillary leak syndrome.
However, CD40L is released by platelets, and patients with
capillary leak syndrome showed decreased pretransplant
platelet counts (Table 1) and a strong correlation between
platelet count and serum CD40L levels. The most likely
explanation for the difference in CD40L serum levels is thus
a difference in CD40L release by platelets during ex vivo
handling of the samples [61]. Although the CD40/CD40L
system is expressed both by endothelial cells and vascular
smooth muscle cells [62] and thus may be important in the
development of capillary leak syndrome [63, 64], the use of
serum samples in our present study makes it impossible to
evaluatewhetherCD40/CD40L is important for the pretrans-
plant predisposition to capillary leak. A possible explanation
for the association between decreased pretransplant platelet
counts and posttransplant capillary leak syndrome could be
a more severe cell damage caused by previous chemotherapy
causing both endothelial cell damage and delayed hematopoi-
etic reconstitution.
Furthermore, we also performed unsupervised hierar-
chal clustering analyses based on the pretransplant cytokine
levels. Cytokines that were detected only in a minority of
patients (Il-1𝛼, IL-1𝛽, IL-2, IL-4, IL-5, IL-6, IL-10, IL-17,
IL-22, CCL3, and TNF-𝛼) were left out from the bioin-
formatical analysis (Figure 4). The frequency of patients
with capillary leak syndrome did not differ significantly
between the two main clusters. The majority of patients later
developed capillary leak syndrome clustered in the upper
part, that is, 18 of the upper 24 patients (Figure 4). In contrast
only six of the lower 32 patients developed capillary leak
syndrome (Figure 4). This observation suggests that many
patients with capillary leak syndrome show similarities in
their pretransplant cytokine profile, but in contrast to the
metabolite clustering (Figure 2) these similarities are not
sufficient to cause statistically significant differences between
main clusters. Thus, our hypothesis is that metabolic differ-
ences are more important than cytokine differences for the
predisposition to capillary leak syndrome in allotransplant
recipients.
4. Conclusions
In our present study we describe an association between
the pretreatment/pretransplant metabolic profile and devel-
opment of fluid retention/capillary leak syndrome after
allogeneic stem cell transplantation. This pretransplant
metabolic profilemay thus represent a predisposition to post-
transplant fluid retention. Bioinformatical analyses suggest
that this association is caused especially by altered purine
and pyrimidine metabolism as well as aminoglycosidation
and eicosanoid metabolism. Several metabolites that show
different levels are known to induce endothelial dysfunction
or altered vascular and renal functions. We have previ-
ously described that pretransplant factors reflect the risk
of acute GVHD after allotransplantation [8, 65], and our
present observations suggest that pretransplant metabolic
factors are important also for the risk of posttransplant fluid
retention.
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Figure 4: Hierarchical clustering based on the cytokine profiles: a study of the first 56 consecutive patients. Based on the pretransplant
cytokine levels we performed an unsupervised hierarchal clustering analysis (Euclidean distance measure withWPGMA linkage). The figure
presents the heat map with corresponding dendrograms. The horizontal cytokine clustering is seen at the top of the figure and the vertical
patient clustering at the left part of the figure. Red color indicates high levels and green color low levels. The right column shows the
distribution of patients with capillary leak syndrome, that is, weight increase ≥5 kg marked with red bars and the others marked with green.
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